Showing results (101-110 of 153) with videos related to
Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall SurvivalMarcelo C Pasquini, Paul K Wallace, Brent Logan, et al.The New England Journal of Medicine|December 12, 2022
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple MyelomaAjai Chari, Monique C Minnema, Jesus G Berdeja, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2016
Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case ForumPere Barba, Linda J Burns, Mark R Litzow, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 7, 2005
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseFrancisco Lopez, Pablo Parker, Auayporn Nademanee, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 14, 2013
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myelomaLuciano J Costa, Mei-Jie Zhang, Xiaobo Zhong, et al.The Lancet. Oncology|October 4, 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialAmrita Krishnan, Marcelo C Pasquini, Brent Logan, et al.Cancer Medicine|October 2, 2025
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple MyelomaNiels W C J van de Donk, Ajai Chari, Thomas Martin, et al.Blood|July 9, 2005
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaAuayporn Nademanee, Stephen Forman, Arturo Molina, et al.JNCI Cancer Spectrum|November 8, 2024
Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetesNikhil Grandhi, Lawrence Liu, Mei Wang, et al.Journal of the American Heart Association|November 26, 2025
Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration StudyTzeyu L Michaud, Mei Wang, Daphne R Friedman, et al.Pageof 16